Related Experiment Videos
Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study"
Eleonora De Martin1, Jean-Marie Michot2, Barbara Papouin3
1AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay Villejuif, DHU Hepatinov, France.
Journal of Hepatology
|October 10, 2018
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Immunologic Consequences of Genomic Instabilities.
Cancer discovery·2026
Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials.
Cancer research communications·2026
Access to early-phase oncology trials: Trajectories and outcomes of more than 26,000 patients referred to a high-volume phase I unit.
European journal of cancer (Oxford, England : 1990)·2026
Development and external validation of a prognostic score associated with poor outcomes in patients receiving immune checkpoint blockade-containing therapies enrolled in early-phase clinical trials.
European journal of cancer (Oxford, England : 1990)·2026
HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Effects of MASH risk genotypes on resmetirom efficacy in patients with MASH and fibrosis.
Journal of hepatology·2026
Survival outcomes after liver transplantation in acute-on-chronic liver failure: A prospective study.
Journal of hepatology·2026
EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy.
Journal of hepatology·2026
Central Nervous System Vasculitis Mimicking Glioma in a Patient With Ulcerative Colitis: A Case Report and Literature Review.
Journal of digestive diseases·2026
3D Iterative Immunofluorescence Imaging on Whole-Mount Samples.
Bio-protocol·2026